JP2014534219A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014534219A5 JP2014534219A5 JP2014539008A JP2014539008A JP2014534219A5 JP 2014534219 A5 JP2014534219 A5 JP 2014534219A5 JP 2014539008 A JP2014539008 A JP 2014539008A JP 2014539008 A JP2014539008 A JP 2014539008A JP 2014534219 A5 JP2014534219 A5 JP 2014534219A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- combination
- combination according
- patient
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 15
- 206010033128 Ovarian cancer Diseases 0.000 claims description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims description 2
- 206010004593 Bile duct cancer Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 102000003915 DNA Topoisomerases Human genes 0.000 claims description 2
- 108090000323 DNA Topoisomerases Proteins 0.000 claims description 2
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims description 2
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000005450 Maxillary Sinus Neoplasms Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims description 2
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims description 2
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 claims description 2
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000004488 maxillary sinus cancer Diseases 0.000 claims description 2
- 208000019303 maxillary sinus carcinoma Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 229910052697 platinum Inorganic materials 0.000 claims description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161551138P | 2011-10-25 | 2011-10-25 | |
| US61/551,138 | 2011-10-25 | ||
| PCT/US2012/061952 WO2013063286A1 (en) | 2011-10-25 | 2012-10-25 | Treatment of patients suffering from cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014534219A JP2014534219A (ja) | 2014-12-18 |
| JP2014534219A5 true JP2014534219A5 (cg-RX-API-DMAC7.html) | 2015-10-29 |
| JP6138140B2 JP6138140B2 (ja) | 2017-05-31 |
Family
ID=47146725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014539008A Active JP6138140B2 (ja) | 2011-10-25 | 2012-10-25 | 癌患者の治療 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20140378404A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2771034B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6138140B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013063286A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102120510B1 (ko) | 2012-11-28 | 2020-06-08 | 넥타르 테라퓨틱스 | 지속 작용성 토포아이소머라제 i 저해제를 이용하는 유방암 치료의 효능을 평가 및 예측하기 위한 방법 |
| WO2025186213A1 (en) | 2024-03-04 | 2025-09-12 | Debiopharm International S.A. | Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8519452D0 (en) * | 1985-08-02 | 1985-09-11 | Erba Farmitalia | Injectable solutions |
| CA2462376C (en) * | 2001-10-03 | 2010-12-14 | Celator Technologies Inc. | Liposome loading with metal ions |
| BRPI0414017B8 (pt) | 2003-09-17 | 2021-05-25 | Nektar Therapeutics Al Corp | pró-fármaco polimérico de múltiplos braços, composição farmacêutica e método para a preparação de um pró-fármaco polimérico de múltiplos braços. |
| ES2436109T3 (es) | 2006-02-09 | 2013-12-27 | Belrose Pharma Inc. | Conjugados poliméricos de múltiples brazos de 7-etil-10-hidroxicamptotecina para el tratamiento del cáncer de mama, del cáncer colorrectal, del cáncer de páncreas, de ovario y de pulmón |
| US20110229572A1 (en) * | 2007-08-16 | 2011-09-22 | Biocompatibles Uk Limited | Delivery of drug combinations |
| CA2780779C (en) | 2009-11-18 | 2020-02-04 | Nektar Therapeutics | Acid salt forms of polymer-drug conjugates and alkoxylation methods |
-
2012
- 2012-10-25 EP EP12783783.9A patent/EP2771034B1/en active Active
- 2012-10-25 JP JP2014539008A patent/JP6138140B2/ja active Active
- 2012-10-25 WO PCT/US2012/061952 patent/WO2013063286A1/en not_active Ceased
- 2012-10-25 US US14/354,080 patent/US20140378404A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123739T1 (el) | Αντισωματα anti-cd38 | |
| HK1209109A1 (en) | Pyridinone and pyridazinone derivatives | |
| MX2014012695A (es) | Derivados de isoindolona. | |
| JP2016538344A5 (cg-RX-API-DMAC7.html) | ||
| CN107427516B8 (zh) | 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法 | |
| HK1199290A1 (en) | Methods and compositions for the treatment and diagnosis of breast cancer | |
| NZ603155A (en) | Phospholipid drug analogs | |
| UA117072C2 (uk) | Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини, і cd3, що не є людським | |
| NZ631062A (en) | Bromodomain inhibitors | |
| MX2014004862A (es) | Formulaciones de polimero acrilico. | |
| EA201290807A1 (ru) | Циклобутановые и метилциклобутановые производные в качестве ингибиторов янус-киназы | |
| NZ706836A (en) | Methods of treating cancer | |
| WO2012149546A3 (en) | Small molecule trail gene induction by normal and tumor cells as an anticancer therapy | |
| MX2015012005A (es) | Inhibidores de bromodominio. | |
| HRP20180698T1 (hr) | Pripravak rnk za liječenje karcinoma pluća ne-malih stanica (nsclc) | |
| EA201390381A1 (ru) | Триазиноксадиазолы | |
| MX347734B (es) | Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas. | |
| EA201391171A1 (ru) | Формы рифаксимина и их применение | |
| MX2015007053A (es) | Compuestos dimericos. | |
| RU2014117707A (ru) | Способ лечения пролиферативного заболевания | |
| WO2013040227A3 (en) | Therapeutic compounds | |
| WO2013023043A3 (en) | Treatment of advanced solid tumors using combination of anti-erbb3 immunotherapy and selected chemotherapy | |
| CY1120395T1 (el) | Παραγωγα στερολης και χρηση αυτων για την αγωγη νοσηματων που περιλαμβανουν μετασχηματισμενα αστροκυτταρα ή για την αγωγη κακοηθων αιμοπαθειων | |
| GB201116017D0 (en) | Bi-aromatic and tri-aromatic compounds as nadph oxidase inhibitors | |
| EA201171360A1 (ru) | Противоопухолевая комбинация, содержащая кабазитаксель и капецитабин |